Expert Interview
A Second Opinion: Evaluating the potential of Nektar's Rezpegaldesleukin (IL-2 inhibitor) in patients with Alopecia Areata
Ticker(s): NKTRInstitution: University of British Columbia
- Professor of Dermatology and Head of Dermatologic Oncology at the University of British Columbia and British Columbia Cancer Agency.
- Currently manages 200 patients with Alopecia Areata and is comfortable discussing low dose IL-2 and Rezpegaldesleukin.
- Authored over 80 peer-reviewed publications and 11 textbook chapters, conducted more than 60 clinical trials since 1989, and leads cancer prevention initiatives.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
